We are live on
!
Find out more
Boston Partners Portfolio holdings
AUM
$95.5B
1-Year Est. Return
28.4%
This Fund
S&P 500
This Quarter
Est. Return
+8.8%
1 Year Est. Return
+28.4%
3 Year Est. Return
+84.58%
5 Year Est. Return
+116.72%
10 Year Est. Return
+426.49%
AUM
$83B
AUM Growth
+$4.08B
(+5.2%)
Cap. Flow
-$2.07B
Cap. Flow
% of AUM
-2.5%
Top 10 Holdings %
Top 10 Hldgs %
13.18%
Holding
730
New
59
Increased
161
Reduced
398
Closed
45
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Keurig Dr Pepper
KDP
|
+$550M |
| 2 |
Fidelity National Information Services
FIS
|
+$353M |
| 3 |
Global Payments
GPN
|
+$263M |
| 4 |
CVS Health
CVS
|
+$175M |
| 5 |
Devon Energy
DVN
|
+$150M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Pfizer
PFE
|
+$433M |
| 2 |
Lowe's Companies
LOW
|
+$277M |
| 3 |
Oracle
ORCL
|
+$226M |
| 4 |
Progressive
PGR
|
+$220M |
| 5 |
Las Vegas Sands
LVS
|
+$167M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 19.96% |
| 2 | Healthcare | 15.3% |
| 3 | Industrials | 15.12% |
| 4 | Technology | 14.91% |
| 5 | Consumer Discretionary | 11.12% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
TAST
626
DELISTED
Carrols Restaurant Group, Inc.
TAST
| $378K | ﹤0.01% |
127,770
-64,784
| -34% | -$217K |
|
627
Allot
ALLT
$373M
| $375K | ﹤0.01% |
+31,564
| New | +$414K |
|
628
iShares Core S&P US Value ETF
IUSV
$27.3B
| $373K | ﹤0.01% |
+4,864
| New | +$361K |
|
629
Fossil Group
FOSL
$248M
| $356K | ﹤0.01% |
34,549
-112,056
| -76% | -$1.35M |
|
630
Covenant Logistics
CVLG
$1.13B
| $355K | ﹤0.01% |
26,840
-2,906
| -10% | -$39.9K |
|
631
Barnes & Noble Education
BNED
$445M
| $352K | ﹤0.01% |
517
-351
| -40% | -$322K |
|
632
Steel Dynamics
STLD
$36.1B
| $352K | ﹤0.01% |
5,672
-1,975
| -26% | -$124K |
|
633
Pediatrix Medical
MD
$2.15B
| $351K | ﹤0.01% |
+12,883
| New | +$345K |
|
|
IVC
634
DELISTED
Invacare Corporation
IVC
| $349K | ﹤0.01% |
128,483
+69,106
| +116% | +$255K |
|
|
NPTN
635
DELISTED
NEOPHOTONICS CORP
NPTN
| $347K | ﹤0.01% |
22,573
-68,193
| -75% | -$897K |
|
636
Stoneridge
SRI
$210M
| $345K | ﹤0.01% |
+17,476
| New | +$369K |
|
637
Asure Software
ASUR
$222M
| $341K | ﹤0.01% |
+43,593
| New | +$381K |
|
638
Bowman Consulting
BWMN
$460M
| $337K | ﹤0.01% |
15,860
-4,084
| -20% | -$69.9K |
|
639
DaVita
DVA
$15.2B
| $332K | ﹤0.01% |
2,920
-100,839
| -97% | -$10.8M |
|
|
THR
640
DELISTED
Thermon Group Holdings
THR
| $329K | ﹤0.01% |
19,408
-6,624
| -25% | -$116K |
|
641
Amazon
AMZN
$2.49T
| $319K | ﹤0.01% |
1,920
+300
| +19% | +$51.3K |
|
642
Transmedics
TMDX
$2.57B
| $317K | ﹤0.01% |
+16,560
| New | +$415K |
|
|
PBPB
643
DELISTED
Potbelly
PBPB
| $312K | ﹤0.01% |
55,973
+6,816
| +14% | +$39.7K |
|
644
Liberty Energy
LBRT
$2.75B
| $305K | ﹤0.01% |
31,489
-14,143
| -31% | -$164K |
|
|
NNDM
645
Nano Dimension
NNDM
$312M
| $304K | ﹤0.01% |
+80,006
| New | +$406K |
|
|
AUGX
646
DELISTED
Augmedix, Inc. Common Stock
AUGX
| $290K | ﹤0.01% |
+92,191
| New | +$334K |
|
|
EEX
647
DELISTED
Emerald Holding
EEX
| $281K | ﹤0.01% |
70,719
| – | – |
|
648
UNIFI
UFI
$121M
| $279K | ﹤0.01% |
12,066
+1,803
| +18% | +$41.1K |
|
649
RGC Resources
RGCO
$231M
| $276K | ﹤0.01% |
11,975
-6,444
| -35% | -$144K |
|
650
Ovid Therapeutics
OVID
$439M
| $270K | ﹤0.01% |
+84,261
| New | +$289K |
|
Similar funds
Boston Partners's Q4 2021 Portfolio in Review
As of Q4 2021, Boston Partners held 730 positions worth $83B, up 5.2% from $78.9B the previous quarter. Its ten largest holdings account for 13% of the portfolio.
Boston Partners's Q4 2021 filing shows 59 new, 161 increased, 398 reduced and 45 closed positions. Its largest new stake was Keurig Dr Pepper: 15,605,496 shares worth $575M. The largest sale was Pfizer, an estimated $433M.
By sector, the portfolio is most concentrated in Financials at 20% of assets, down from 22% a quarter earlier, followed by Healthcare and Industrials.
- Boston Partners's largest Q4 2021 buy was Keurig Dr Pepper: 15,605,496 shares worth $575M.
- Boston Partners added most to Fidelity National Information Services in Q4 2021, an estimated $353M increase.
- Boston Partners's biggest Q4 2021 reduction was Pfizer, cutting an estimated $433M.
- Boston Partners fully exited CyrusOne Inc Common Stock in Q4 2021, selling an estimated $137M.
- Boston Partners's ten largest holdings make up 13% of its $83B portfolio in Q4 2021.
- Boston Partners opened 59 new positions and closed 45 in Q4 2021.
- Boston Partners's portfolio value rose 5.2% quarter-over-quarter to $83B.
Based on Boston Partners's 13F filing for Q4 2021, filed 4 Feb 2022.